Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study

The Lancet Oncology

Volumn 17, Issue 9, 2016, Pages 1295-1305

  Villani, Anita ^a   Shore, Ari ^a   Wasserman, Jonathan D ^a   Stephens, Derek ^a   Kim, Raymond H ^c   Druker, Harriet ^a,b   Gallinger, Bailey ^a,b   Naumer, Anne ^d   Kohlmann, Wendy ^d   Novokmet, Ana ^a   Tabori, Uri ^a   Tijerin, Marta ^b   Greer, Mary Louise C ^b   Finlay, Jonathan L ^e   Schiffman, Joshua D ^d   Malkin, David ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANADA; CANCER RISK; CHILD; CLINICAL ARTICLE; COLONOSCOPY; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; FOLLOW UP; GENE DOSAGE; GENE SEQUENCE; GENETIC VARIABILITY; GERMLINE MUTATION; HUMAN; INFORMED CONSENT; LIMIT OF QUANTITATION; MALE; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE; UNITED STATES; AGED; CANCER STAGING; DIAGNOSTIC IMAGING; GENETIC PREDISPOSITION; GENETICS; HEALTH SURVEY; HETEROZYGOTE; INFANT; LI-FRAUMENI SYNDROME; METABOLISM; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; INFANT; INFANT, NEWBORN; LI-FRAUMENI SYNDROME; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; NEOPLASMS; POPULATION SURVEILLANCE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84994545580     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30249-2     Document Type: Article

References (23)

1. 1 Villani, A, Tabori, U, Schiffman, J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 12 (2011), 559–567.
2. 2 Jhaveri, AP, Bale, A, Lovick, N, et al. The benefit and burden of cancer screening in Li-Fraumeni syndrome: a case report. Yale J Biol Med 88 (2015), 181–185.
3. 3 Li-Fraumeni whole-body MRI study. http://www.dana-farber.org/uploadedFiles/Library/adult-care/treatment-and-support/centers-and-programs/cancer-genetics-and-prevention/li-fraumeni-whole-body.pdf (accessed Aug 17, 2015).
4. 4 Nichols, KE, Malkin, D, Garber, JE, Fraumeni, JF Jr, Li, FP, Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 10 (2001), 83–87.
5. 5 Le Bihan, C, Moutou, C, Brugières, L, Feunteun, J, Bonaïti-Pellié, C, ARCAD: a method for estimating age-dependent disease risk associated with mutation carrier status from family data. Genet Epidemiol 12 (1995), 13–25.
6. 6 Jasperson, KW, Kohlmann, W, Gammon, A, et al. Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families. Fam Cancer 13 (2014), 257–265.
7. 7 Friedman, DN, Lis, E, Sklar, CA, et al. Whole-body magnetic resonance imaging (WB-MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: a pilot study. Pediatr Blood Cancer 61 (2014), 1440–1444.
8. 8 Anupindi, SA, Bedoya, MA, Lindell, RB, et al. Diagnostic performance of whole-body MRI as a tool for cancer screening in children with genetic cancer-predisposing conditions. AJR Am J Roentgenol 205 (2015), 400–408.
9. 9 Nogueira, ST, Lima, EN, Nobrega, AF, et al. (18)F-FDG PET-CT for surveillance of Brazilian patients with Li-Fraumeni syndrome. Front Oncol, 5, 2015, 38.
10. 10 Masciari, S, Van den Abbeele, AD, Diller, LR, et al. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA 299 (2008), 1315–1319.
11. 11 Lammens, CR, Bleiker, EM, Aaronson, NK, et al. Regular surveillance for Li-Fraumeni syndrome: advice, adherence and perceived benefits. Fam Cancer 9 (2010), 647–654.
12. 12 Gopie, JP, Vasen, HF, Tibben, A, Surveillance for hereditary cancer: does the benefit outweigh the psychological burden?—a systematic review. Crit Rev Oncol Hematol 83 (2012), 329–340.
13. 13 Wasserman, JD, Novokmet, A, Eichler-Jonsson, C, et al. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study. J Clin Oncol 33 (2015), 602–609.
14. 14 Michalkiewicz, E, Sandrini, R, Figueiredo, B, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 22 (2004), 838–845.
15. 15 Riedl, CC, Luft, N, Bernhart, C, et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol 33 (2015), 1128–1135.
16. 16 Lauby-Secretan, B, Scoccianti, C, Loomis, D, et al. Breast-cancer screening—viewpoint of the IARC Working Group. N Engl J Med 372 (2015), 2353–2358.
17. 17 Warner, E, Hill, K, Causer, P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 29 (2011), 1664–1669.
18. 18 Wong, P, Verselis, SJ, Garber, JE, et al. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology 130 (2006), 73–79.
19. 19 National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf, March 15, 2016 (accessed March 18, 2016).
20. 20 Masciari, S, Dewanwala, A, Stoffel, EM, et al. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med 13 (2011), 651–657.
21. 21 Ariffin, H, Chan, AS, Oh, L, et al. Frequent occurrence of gastric cancer in Asian kindreds with Li-Fraumeni syndrome. Clin Genet 88 (2015), 450–455.
22. 22 Yurgelun, MB, Masciari, S, Joshi, VA, et al. Germline mutations in patients with early-onset colorectal cancer in the Colon Cancer Family Registry. JAMA Oncol 1 (2015), 214–221.
23. 23 Bougeard, G, Renaux-Petel, M, Flaman, JM, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol 33 (2015), 2345–2352.